Esophageal Squamous Cell Carcinoma clinical trials
The registry lists 676 studies for Esophageal Squamous Cell Carcinoma across more than 10 countries. 267 are recruiting or about to start. 522 of them are mainly about Esophageal Squamous Cell Carcinoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.
ClinicalTrials.gov finds 1,039 studies for Esophageal Squamous Cell Carcinoma. How that becomes 674 here
This page counts the studies the registry files under Esophageal Squamous Cell Carcinoma, and those it files under no condition that list Esophageal Squamous Cell Carcinomathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 1,039Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −11List Esophageal Squamous Cell Carcinoma as a condition, but the registry did not file them under itMost often written as “Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8” (4), “Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8” (4), and “Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8” (4). The registry filed them under other conditions only, most often Esophageal Neoplasms (6) and Pancreatic Neoplasms (3).
- −354Match it another way153 name it in the title, 1 in a keyword, and 200 by a synonym or other text the search reads.
- 674The count on this page50 of them list Esophageal Squamous Cell Carcinoma in their own words; the registry filed them under no condition.
Get an email when these change. Save the Esophageal Squamous Cell Carcinoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Fudan University (37) · Sun Yat-sen University (32) · The First Affiliated Hospital of Zhengzhou University (19) · Peking University (19) · Tianjin Medical University Cancer Institute and Hospital (17) · Hebei Medical University Fourth Hospital (13) · Shanghai Zhongshan Hospital (12) · Shanghai Chest Hospital (12)
What is being tested here
Drugs under test in Esophageal Squamous Cell Carcinoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Tislelizumab | 12 | 4 | 21 |
| Adebrelimab | 11 | 0 | 14 |
| Paclitaxel | 10 | 6 | 42 |
| Sintilimab | 9 | 5 | 21 |
| Toripalimab | 9 | 3 | 16 |
| Cisplatin | 6 | 8 | 43 |
| Anlotinib | 6 | 1 | 13 |
| Albumin-Bound Paclitaxel | 6 | 0 | 9 |
| Sacituzumab tirumotecan | 6 | 0 | 6 |
| Pembrolizumab | 5 | 3 | 16 |
Drug classes tested here Immune checkpoint inhibitors 81 open · Tyrosine kinase inhibitors (TKIs) 16 open · Antimitotic agents 11 open · Antibody-drug conjugates (ADCs) 9 open · Antimetabolites 5 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Nov 2026Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC · Phase 3 · Rui-hua Xu, MD, PhD
- Dec 2026A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer · Phase 3 · Beijing Konruns Pharmaceutical Co., Ltd.
- Dec 2026Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma · Phase 3 · Peking Union Medical College Hospital
- Dec 2026Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer · Phase 3 · Karolinska University Hospital
- Jan 2027A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell Carcinoma · Phase 3 · Shanghai Runshi Pharmaceutical Technology Co., Ltd
- May 2027Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma · Phase 3 · Shanghai Junshi Bioscience Co., Ltd.
- Jun 2027Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC · Phase 3 · AstraZeneca
- Sep 2027Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy · Phase 3 · Ye jinjun
- Nov 2026Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma · National Taiwan University Hospital
- Nov 2026Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients · Jiangxi Provincial Cancer Hospital
Who these studies take
Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger. 3 (2%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 8 (4%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (2%) | 3 (2%) |
| 18 | 169 (94%) | 169 (94%) |
| 30 | 174 (97%) | 174 (97%) |
| 40 | 174 (97%) | 174 (97%) |
| 50 | 174 (97%) | 174 (97%) |
| 65 | 174 (97%) | 174 (97%) |
| 75 | 168 (93%) | 168 (93%) |
| 85 | 88 (49%) | 88 (49%) |
Across all 676 studies, recruiting or not: 44% stop at 75 or younger and 1% at 65; 3% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Esophageal Squamous Cell Carcinoma studies take
Of 173 phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 40 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 42 mo34–68 · 42 studies | — | — |
| Phase 2 | 40 mo28–52 · 173 studies | — | 41 mo30–55 · 153 studies |
| Phase 3 | 66 mo37–76 · 44 studies | — | — |
| Interventional, no phase | 46 mo25–… · 37 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting3
- Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal DissectionNov 6, 2026NCT07343869
- QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell CarcinomaNov 2, 2026NCT07049185
- Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter StudyOct 23, 2026NCT07246330
Stopped1
Newly registered5
- Retrospective Analysis of a Psoralea Corylifolia (Buguzhi)-Containing TCM Formula for Gastrointestinal CancersNov 12, 2026NCT07932951
- A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical ResectionNov 9, 2026NCT07924111
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNov 2, 2026NCT07909031
- Station-Specific Lymph Node Metastasis After Neoadjuvant Chemoimmunotherapy for Middle Thoracic Esophageal Squamous Cell CarcinomaOct 29, 2026NCT07902544
- Radiotherapy Target Volume in Locally Advanced Esophageal Squamous Cell Carcinoma in the Immunotherapy EraOct 19, 2026NCT07879898
Studies
Recruiting first, then most recently updated. Showing 50 of 676. Browse all 676 → or search them.
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingNCT06780111Phase 1/216 countries
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesRecruitingNCT07503808Phase 13 countries
- A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)RecruitingNCT07405151Phase 1/212 countries
- A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical ResectionNot yet recruitingNCT07924111Phase 3
- Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal DissectionRecruitingNCT073438691 country
- Standardized Management of Esophageal Fistula in Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07353541
- Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE TrialRecruitingNCT07439484Not applicable1 country
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsRecruitingNCT07090499Phase 16 countries
- QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07049185Phase 21 country
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07909031Phase 1/21 country
- Study of XB010 in Subjects With Solid TumorsRecruitingNCT06545331Phase 12 countries
- Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCCRecruitingNCT06510660Phase 21 country
- Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingNCT06601309Phase 21 country
- A Study of MGC026 in Participants With Advanced Solid TumorsRecruitingNCT06242470Phase 13 countries
- A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid TumorsRecruitingNCT06747585Phase 1/28 countries
- A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway AlterationsRecruitingNCT07109726Phase 1/25 countries
- A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid TumorsRecruitingNCT07730021Phase 1/22 countries
- A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCCRecruitingNCT07733180Phase 21 country
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Phase 317 countries
- Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter StudyRecruitingNCT07246330Phase 31 country
- Breath Research Narrow Validation for Gastrointestinal Cancer DetectionRecruitingNCT077145381 country
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsRecruitingNCT05914116Phase 1/24 countries
- SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Phase 21 country
- A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United StatesRecruitingNCT07554521Phase 21 country
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400RecruitingNCT06084481Phase 18 countries
- A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal CancerRecruitingNCT05563766Phase 21 country
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Phase 1/214 countries
- Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell CarcinomaRecruitingNCT06342167Phase 21 country
- Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT07339488Phase 21 country
- Radiotherapy Target Volume Delineation in Locally Advanced Esophageal Cancer in the Immunotherapy EraRecruitingNCT078586301 country
- Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07244978Phase 21 country
- Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramRecruitingNCT06265285Phase 21 country
- Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07505186Phase 21 country
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsRecruitingNCT07189871Phase 1/21 country
- A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsRecruitingNCT07085091Phase 11 country
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsRecruitingNCT07277413Phase 11 country
- A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07229313Phase 12 countries
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisRecruitingNCT06047379Phase 1/21 country
- PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCCNot yet recruitingNCT07836049Phase 21 country
- Sacituzumab Govitecan for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06329869Phase 21 country
- Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph NodesNot yet recruitingNCT07830355Phase 2
- Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07823270Phase 21 country
- A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07751341Phase 21 country
- Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and SurgeryNot yet recruitingNCT078229061 country
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell CarcinomasRecruitingNCT07217171Phase 11 country
- Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsRecruitingNCT06535607Phase 212 countries
- Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal CancerRecruitingNCT07811752Phase 21 country
- A Study of IDP-001 in Advanced or Metastatic Solid TumorsRecruitingNCT07602842Phase 1/21 country
- Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07799077Phase 21 country
- Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCCRecruitingNCT07796113Phase 21 country